Mixed Results Of Zoll's LifeVest Trial Sparks Reaction From Cardiologists
Results of VEST, the first randomized, multi-center trial of Zoll's LifeVest wearable cardioverter defibrillator for prevention of sudden cardiac death following a heart attack, missed its primary endpoint, a reduction in sudden cardiac deaths. However, patients randomized to LifeVest had lower overall risk of mortality than the patients randomized to standard medical therapy. The conflicting results triggered a lot of discussion among cardiologists online.
You may also be interested in...
New clinical data with the potential to change clinical practice will be presented at the 2018 American College of Cardiology Scientific Session and Expo in Orlando, Fla., Mar. 10-12. Among the planned late-breaking trials and featured research presentations is a study of Zoll's LifeVest wearable external cardioverter-defibrillator following a heart attack; new results from a trial of Abbott's Amplatzer PFO-closure device, and long-term data on Abbott's HeartMate 3 ventricular assist device.
Favorable results of the Guidant-sponsored MADIT II trial could increase the U.S. patient population that could benefit from implantable cardioverter defibrillator therapy from 300,000 to about 600,000, Guidant says
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.